Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham
CPT: Pharmacometrics & Systems Pharmacology · 2025-02 · 14 (2) · 257-267
DOI: 10.1002/psp4.13264 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 05.11.2024. Verfasst von Ryan L Crass und 6 weiteren Autor:innen. Beteiligte Einrichtung: A2-Ai, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Complement Inactivating Agents, Geographic Atrophy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Apellis Pharmaceuticals.
Abstract (Originalsprache)
Pegcetacoplan is a complement C3/C3b inhibitor indicated for the treatment of geographic atrophy (GA). A population pharmacokinetic (PK)/pharmacodynamic (PD) analysis of pegcetacoplan used GA lesion area measurements from three clinical studies to determine the effect of pegcetacoplan exposure on GA progression. A base disease progression model was developed using data from sham‐treated eyes and untreated fellow eyes, followed by treatment effect assessment in dose–response and PK/PD models. In total, 1501 patients from FILLY (NCT02503332), OAKS (NCT03525613), and DERBY (NCT03525600) received intravitreal pegcetacoplan 15 mg monthly or every other month (EOM) or sham treatment monthly or EOM and were included in the population analysis of lesion area. Disease progression over time was adequately described as linear‐with‐time over the 24‐month maximal study duration. Disease‐specific covariates associated with slower lesion growth were unilateral, unifocal, and subfoveal GA lesions and >20 intermediate or large drusen groups (≥63 μm) at baseline. The dose–response model estimated 0.80‐fold (95% CI: 0.75, 0.84) and 0.83‐fold (95% CI: 0.78, 0.87) reductions in GA lesion growth rate with pegcetacoplan monthly and EOM, respectively, versus sham. A relationship between vitreous humor concentration and GA lesion growth rate was quantified as 2.6% per unit of log‐transformed vitreous pegcetacoplan concentration in the PK/PD model. PK/PD predictions of treatment effect based on exposure (pegcetacoplan monthly: 0.80 [90% CI: 0.77, 0.84]; pegcetacoplan EOM: 0.83 [90% CI: 0.80, 0.86]) were consistent with predictions based on dose response. These results support the benefit of pegcetacoplan administered monthly or EOM in slowing GA lesion growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- A2-Ai, Ann Arbor, Michigan, USA.
- Apellis Pharmaceuticals, Waltham, Massachusetts, USA.
- New England Eye Center, Boston, Massachusetts, USA.
ORCID-Profile: Ryan L Crass, Francois Gaudreault, Elizabeth Lusk, Caroline R Baumal
Förderung
- Apellis Pharmaceuticals
Zitieren
APA
Crass, R. L., Prem, K., Gaudreault, F., Lusk, E., Ribeiro, R., Chapel, S., & Baumal, C. R. (2025). Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. CPT: Pharmacometrics & Systems Pharmacology, 14(2), 257-267. https://doi.org/10.1002/psp4.13264
Vancouver
Crass RL, Prem K, Gaudreault F, Lusk E, Ribeiro R, Chapel S, et al. Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(2):257-267. doi:10.1002/psp4.13264
BibTeX
@article{Crass2025,
author = {Crass, Ryan L and Prem, Komal and Gaudreault, Francois and Lusk, Elizabeth and Ribeiro, Ramiro and Chapel, Sunny and Baumal, Caroline R},
title = {Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
volume = {14},
number = {2},
pages = {257--267},
doi = {10.1002/psp4.13264}
}
EUVIMED